Abigail Brooks, MA

Findings suggest post-stroke dysphagia is associated with adverse psychosocial outcomes at 3 months, emphasizing the need for comprehensive rehabilitation strategies.

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Phase 3 STRIVE-ON Safety Trial results were presented at the 2025 Neurocritical Care Society annual meeting and suggest GTx-104’s viability over oral nimodipine.

The approval offers the flexibility of self-administration from the start of treatment for UC, building on the prior approval of SC induction in Crohn’s disease.

The guideline offers 12 conditional recommendations for the diagnosis and management of gastroparesis, emphasizing individualized care and calling for more research.

The 2025 guideline updates previous recommendations made in the 2021 glomerular disease guideline based on recent therapeutic advances in IgAN.

The label update expands the treatment eligible population to include dystrophic epidermolysis bullosa patients from birth and allows at-home application.

Intercept Pharmaceuticals has voluntarily withdrawn obeticholic acid from the US market following a request from the FDA.

Upon further review of the sNDA, the Agency indicated an advisory committee for sparsentan in FSGS is no longer needed.

For the first time, the FDA has accepted the initiation of the qualification of an NIT as a noninvasive surrogate endpoint in drug development for MASH.

The first patient in the ongoing Multi-Patient Expanded Access study has surpassed 7 months kidney function, and a second patient has been successfully transplanted.

The death rate from high blood pressure-related kidney disease increased by 48% from 1999-2023, with notable disparities by race, ethnicity, sex, and region.

Findings highlight a 33% increase in 1-year and nearly 50% increase in 5-year post-transplant survival with a living versus deceased donor transplant.

WVE-006 drove production of M-AAT, which is protective of lung function, and reduced mutant Z-AAT, a cause of liver disease.

Check out renal FDA news and new research on pediatric kidney stone management, CKD trends, spironolactone for dialysis patients, and more.

Check out expert perspectives on unmet needs and advances in gastroparesis and new research on C. diff, IBS, and more in this August 2025 recap.

Check out expert perspectives on semaglutide’s FDA approval for MASH and new research on PBC, infectious disease screening, and more in this August 2025 recap.

Vancomycin was linked to a higher risk of acute kidney injury than alternative antibiotics, underscoring the need for appropriate prevention strategies.

The 9-week intervention targeting positive psychological wellbeing in IBS was feasible, well-accepted, and linked to improvements in IBS-related outcomes.

Any alcohol intake was linked to a greater risk of liver mortality, but healthy diet and physical activity lowered this risk across all drinking patterns.

The REMS label update reduces the frequency of liver function monitoring and removes the embryo-fetal toxicity monitoring requirement.

A trio of experts reflect on unmet needs in gastroparesis, from diagnosis to treatment, and discuss advances that could shape the future of care.

People with PBC and pruritus had a greater negative impact on HRQoL and reduced activity compared to those without pruritus, infrequently using medication.

Orforglipron met the primary and all key secondary endpoints in patients with obesity/overweight and type 2 diabetes, supporting global regulatory submissions.

The cross-sectional analysis of NHANES data highlights obesity and overweight’s influence on the development of obesity-related conditions in US youth.

Targeted C.difficile screening and prophylaxis focused on high-risk immunocompromised patients was linked to reductions in hospital-onset infection.

Healthcare costs and resource utilization were significantly greater in individuals with ASCVD and CKD with systemic inflammation versus those without.

Semaglutide 2.4 mg use was linked to lower medical costs and inpatient resource utilization among patients with overweight or obesity and heart failure.

Hydroxychloroquine reduced proteinuria levels with an acceptable safety profile but had limited effects on overall eGFR in primary glomerular diseases.

ACHIEVE trial data showed spironolactone 25 mg did not reduce cardiovascular mortality and hospitalization due to heart failure in dialysis patients.